←  BACK TO CALL FOR ABSTRACTS

 

Format

A research abstract must include the following information (limited to 2,140 characters, not including spaces):
 

• Title
• Brief statement of Purpose of the study (goal or hypothesis being tested)
• Statement of Methods and procedures used
• Summary of Results, presented in sufficient detail to support the conclusion
• Study Conclusion
   

Note: abstracts undergo a blind review process; therefore, abstain from using institution and corporate names within the abstract. If accepted, you may update your presentation accordingly.
 

Authors

The Full Name, Affiliation, Email Address, and Disclosure Statement for the Presenting Author and each co-author must be included. There is no limit to the number of authors, and author information is not counted towards the character limit.

The Presenting Author will be the only author to receive notification of acceptance/rejection of a submitted abstract; therefore, it is the Presenting Author's responsibility to notify all co-authors regarding the outcome of an abstract submission.
 

Submission Categories

The online system will prompt you to select a PRIMARY core therapy/disease-focused AREA (and up to 3 applicable SECONDARY therapy areas). Based on your PRIMARY core therapy selection, you will then select ONE category from the below list:

PRIMARY AREA: Advanced Heart Failure and Transplantation (HEART)

• Access to Care
• Cardiogenic Shock
• Caregiver and Psychosocial Aspects
• Clinical Ex-Vivo Perfusion and Preservation
• Compliance/Adherence to Care
• Complications Other
• Congenital Heart Disease Management
• Coronary Artery Vasculopathy
• COVID-19
• Critical Care Medicine
• Diagnostics/Patient Management
• Donor Management and Organ Allocation
• Economics, Ethics, Public Policy
• Immunology, Inflammation, Immunosuppression (Basic Science)
• Immunology, Inflammation, Immunosuppression (Clinical)
• Infectious Diseases - Diagnostics and Complications
• Infectious Diseases - Management and Therapeutics
• Models of Organ Preservation, Perfusion and Graft Injury (Basic Science)
• Other (Basic Science/Translational Research)
• Other (Clinical)
• Outcomes
• Palliative Care
• Pathology
• Patient Care Pathways
• Patient Selection for Transplant and/or Advanced Therapies
• Peri-operative/Intra-operative Management
• Pharmacology and Therapeutics
• Physiology
• Primary Graft Dysfunction
• Quality Improvement
• Quality of Life
• Rejection - Antibody Mediated (AMR)
• Rejection - Cellular
• Symptom Management/Self Care
• Xenotransplantation/Regenerative Medicine/Artificial Organs (Basic Science)
   

PRIMARY AREA: Advanced Lung Failure and Transplantation (LUNG)

• Access to Care
• Caregiver and Psychosocial Aspects
• Chronic Lung Allograft Dysfunction (CLAD)
• Clinical Ex-Vivo Perfusion and Preservation
• Compliance/Adherence to Care
• Complications Other
• Congenital Lung Disease Management
• COVID-19
• Critical Care Medicine
• Diagnostics/Patient Management
• Donor Management and Organ Allocation
• ECMO/Short-Term Support
• Economics, Ethics, Public Policy
• Immunology, Inflammation, Immunosuppression (Basic Science)
• Immunology, Inflammation, Immunosuppression (Clinical)
• Infectious Diseases - Diagnostics and Complications
• Infectious Diseases - Management and Therapeutics
• Models of Organ Preservation, Perfusion and Graft Injury (Basic Science)
• Other (Basic Science/Translational Research)
• Other (Clinical)
• Outcomes
• Palliative Care
• Pathology
• Patient Care Pathways
• Patient Selection for Transplant and/or Advanced Therapies
• Peri-operative/Intra-operative Management
• Pharmacology and Therapeutics
• Physiology
• Primary Graft Dysfunction
• Quality Improvement
• Quality of Life
• Rejection - Antibody Mediated (AMR)
• Rejection - Cellular
• Symptom Management/Self Care
• Xenotransplantation/Regenerative Medicine/Artificial Organs (Basic Science)
   

PRIMARY AREA: Mechanical Circulatory Support (MCS)

• Access to MCS Placement and Care
• Bleeding/Thrombosis/Anticoagulation
• Caregiver and Psychosocial Aspects
• Compliance/Adherence to Care
• Complications Other
• COVID-19
• Critical Care Medicine
• Devices and Engineering
• Diagnostics/Patient Management
• ECMO/Short-Term Support
• Economics, Ethics, Public Policy
• Immunology, Inflammation (Basic Science)
• Immunology, Inflammation (Clinical) •
• Infectious Diseases - Diagnostics and Complications
• Infectious Diseases - Management and Therapeutics
• Other (Basic Science/Translational Research)
• Other (Clinical)
• Outcomes
• Palliative Care
• Patient Care Pathways
• Patient Selection for Transplant and/or Advanced Therapies
• Pediatric MCS
• Peri-operative/Intra-operative Management
• Pharmacology and Therapeutics
• Physiology
• Quality Improvement
• Quality of Life
• Surgical Techniques
• Symptom Management/Self Care
   

PRIMARY AREA: Pulmonary Vascular Disease (PVD)

• Caregiver and Psychosocial Aspects
• Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
• Compliance/Adherence to Care
• Complications Other
• COVID-19
• Critical Care Medicine
• Diagnostics/Patient Management
• Economics, Ethics, Public Policy
• Etiology
• Immunology, Inflammation (Basic Science)
• Immunology, Inflammation (Clinical)
• Other (Basic Science/Translational Research)
• Other (Clinical)
• Outcomes
• Palliative Care
• Pathology
• Patient Care Pathways
• Patient Selection for Transplant and/or Advanced Therapies
• Pediatric Pulmonary Hypertension
• Peri-operative/Intra-operative Management
• Pharmacology and Therapeutics
• Physiology
• Pulmonary Hypertension due to Heart or Lung Disease
• Quality Improvement
• Quality of Life
• RV Failure/Complications
• Symptom Management/Self Care
   

Publication

All accepted Research Abstracts will be published exactly as submitted in the April 2021 Supplement of the Journal of Heart and Lung Transplantation.

Visit our FAQ Page for answers to common submission questions.